Barry Callebaut has halted manufacturing operations at its Weize chocolate plant in Belgium as a precautionary measure while conducting its root cause analysis and risk assessment after detecting salmonella in a production lot.
The company identified lecithin as the source of the contamination.
All chocolate products manufactured at the facility since June 25 have been placed on hold.
After the analysis, the lines will be cleaned and sanitized before production can resume.
Barry Callebaut, which informed the Belgian food authorities (FAVV) about the incident, said that their robust food safety programs allowed them to identify lecithin as the source of the contamination quickly.
The company added that they are reaching out to all customers who may have received impacted products.
The news comes after Ferrero temporarily suspended production at its Arlon facility in Belgium after the site was linked to a salmonella outbreak.


FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
Trump Backs Review of U.S. Childhood Vaccine Schedule After Hepatitis B Policy Change
U.S. Stock Futures Slip After CPI-Fueled Rally as Markets Weigh Economic Uncertainty
U.S. Reveals 2026 Medicare Star Ratings: Aetna, UnitedHealth Lead in Quality Scores
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking.
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation
Precious Metals Rally as Silver and Platinum Outperform on Rate Cut Bets
Gold and Silver Surge as Safe Haven Demand Rises on U.S. Economic Uncertainty
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment
BOJ Poised for Historic Rate Hike as Japan Signals Shift Toward Monetary Normalization
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate
Singapore Growth Outlook Brightens for 2025 as Economists Flag AI and Geopolitical Risks
Trump Signs Executive Order to Boost AI Research in Childhood Cancer
Major Drugmakers Slash U.S. Prices and Sell Directly to Patients Amid Trump’s Push for Affordable Medicines 



